NCT04459078 is a Phase 2 clinical trial of Camrelizumab in Adenocarcinoma of the Lung, sponsored by Hunan Cancer Hospital.

Who is sponsoring NCT04459078?

NCT04459078 is sponsored by Hunan Cancer Hospital.

What drugs are being tested in NCT04459078?

Interventions in NCT04459078: Camrelizumab, Albumin Paclitacxel, Apatinib.

What condition does NCT04459078 study?

NCT04459078 studies Adenocarcinoma of the Lung.

Is NCT04459078 still recruiting?

NCT04459078 is currently status unknown. Last updated 2 December 2022.

Last reviewed 2022-12-02 · How we verify

NCT04459078

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

Status unknown Phase 2 Last updated 2 December 2022

What this trial tests

Phase 2 trial testing Camrelizumab in Adenocarcinoma of the Lung in 63 participants. Status unknown.

Timeline

26 August 2020

Primary endpoint
15 May 2023

15 July 2023

Quick facts

Lead sponsor	Hunan Cancer Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	63
Start date	26 August 2020
Primary completion	15 May 2023
Estimated completion	15 July 2023
Sites	3 locations across China

Drugs / interventions tested

Camrelizumab — full drug profile →
Albumin Paclitacxel — full drug profile →
Apatinib (Apatinib) — full drug profile →

Conditions studied

Adenocarcinoma of the Lung — all drugs for Adenocarcinoma of the Lung →

Sponsor

Hunan Cancer Hospital

Who can join

18 and older, any sex, with Adenocarcinoma of the Lung. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a single arm, open label, national multicenter study, to explore the efficacy and safety of the combination of Camrelizumab, apatinib and albumin paclitaxel in advanced untreated EGFR Wild Type and ALK-negative Lung Adenocarcinoma. The study does not consider PD-L1 expression, but tumor samples need to be explored by PD-L1 detection and other exploratory analysis.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
Wu M, Huang Q, Xie Y, Wu X, et al · · 2022 · cited 336× · PMID 35279217 · DOI 10.1186/s13045-022-01242-2
Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy.
Choi Y, Jung K. · · 2023 · cited 100× · PMID 37907742 · DOI 10.1038/s12276-023-01114-w
Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase II study.
Pu X, Lin G, Xiao M, Lin J, et al · · 2024 · cited 9× · PMID 38261958 · DOI 10.1016/j.eclinm.2023.102403
Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?
Timon-David E, Perez C, Rodallec A. · · 2022 · cited 2× · PMID 36365144 · DOI 10.3390/pharmaceutics14112326

Verify or expand the search:

Other trials of Camrelizumab

Trials testing the same drug.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
NCT07466901 — A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Rad · NA · not yet recruiting
NCT07527026 — A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant T · Phase 2 · recruiting
NCT07266350 — A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for th · not yet recruiting

Other recruiting trials for Adenocarcinoma of the Lung

Currently open trials in the same condition.

NCT01345851 — Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemother · NA · active not recruiting

Other Hunan Cancer Hospital trials

Trials by the same sponsor.

NCT07314216 — Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcin · Phase 2 · not yet recruiting
NCT07083687 — Lorlatinib in ROS1+ NSCLC With Brain Metastasis · Phase 2 · not yet recruiting
NCT07098026 — Shenqi Fuwei Mixture Combined With Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric Cancer · NA · recruiting
NCT06840704 — Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer · Phase 3 · recruiting
NCT06788002 — LDRT and Chemoimmunotherapy in NPC With Liver Metastasis · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04459078 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hunan Cancer Hospital
Last refreshed: 2 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04459078.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing